| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D | 2018-12-21 | VERTEX PHARMACEUTICALS INC / MA | CRISPR Therapeutics AG | 5,250,000 | 10.1% | EDGAR |
| SC 13D/A | 2018-02-13 | GLAXOSMITHKLINE PLC | CRISPR Therapeutics AG | 3,265,627 | 7.1% | EDGAR |
| SC 13G/A | 2018-02-12 | New Enterprise Associates 15, L.P. | CRISPR Therapeutics AG | 3,216,021 | 7.8% | EDGAR |
| SC 13D/A | 2018-02-08 | CELGENE CORP /DE/ | CRISPR Therapeutics AG | 2,800,772 | 6.1% | EDGAR |
| SC 13D/A | 2018-01-16 | Abingworth LLP | CRISPR Therapeutics AG | 1,897,618 | 4.0% | EDGAR |
| SC 13D/A | 2017-12-26 | CELGENE CORP /DE/ | CRISPR Therapeutics AG | 3,306,819 | 8.1% | EDGAR |
| SC 13D/A | 2017-12-06 | CELGENE CORP /DE/ | CRISPR Therapeutics AG | 3,722,534 | 9.1% | EDGAR |
| SC 13D/A | 2017-09-15 | Versant Venture Capital IV, L.P. | CRISPR Therapeutics AG | 2,736,032 | 6.7% | EDGAR |
| SC 13D/A | 2017-08-14 | Abingworth LLP | CRISPR Therapeutics AG | 2,158,017 | 5.3% | EDGAR |
| SC 13G | 2017-02-13 | VERTEX PHARMACEUTICALS INC / MA | CRISPR Therapeutics AG | 3,186,586 | 8.0% | EDGAR |
| SC 13G | 2017-02-06 | New Enterprise Associates 15, L.P. | CRISPR Therapeutics AG | 3,216,021 | 8.1% | EDGAR |
| SC 13D/A | 2016-11-07 | GLAXOSMITHKLINE PLC | CRISPR Therapeutics AG | 3,250,627 | 8.3% | EDGAR |
| SC 13D | 2016-11-03 | Abingworth LLP | CRISPR Therapeutics AG | 2,604,314 | 6.6% | EDGAR |
| SC 13D | 2016-11-03 | Versant Venture Capital IV, L.P. | CRISPR Therapeutics AG | 4,104,045 | 10.4% | EDGAR |
| SC 13D | 2016-10-31 | CELGENE CORP /DE/ | CRISPR Therapeutics AG | 4,834,980 | 12.3% | EDGAR |
| SC 13D | 2016-10-28 | GLAXOSMITHKLINE PLC | CRISPR Therapeutics AG | 3,250,627 | 8.3% | EDGAR |
| SC 13D | 2016-10-28 | Bayer Global Investments B.V. | CRISPR Therapeutics AG | 5,105,330 | 12.8% | EDGAR |